Verona Pharma plc has received approval from the U.S. Food and Drug Administration (FDA) for Ohtuvayre (ensifentrine), the first inhaled product with a novel mechanism of action available for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients in more than 20 years. Ligand Pharmaceuticals Incorporated, a partner of Verona, earned a $5.8 million milestone payment upon FDA approval of Ohtuvayre and will earn an additional $13.8 million upon its commercia...